Radionuclide monitoring of left ventricular function after sublingual nifedipine administration at rest and during moderate physical activity.
BACKGROUND
This study investigates the acute effects of nifedipine administration on left ventricular (LV) function in patients with different degrees of heart failure at a fixed heart rate under resting conditions and during moderate physical activity.


RESULTS
Eleven patients with non-rate-responsive DDD pacemakers were studied. According to baseline LV ejection fraction, patients were divided into 2 groups: 6 patients with an ejection fraction of less than 50% (group 1) and 5 patients with an ejection fraction of 50% or more (group 2). LV function was monitored by a radionuclide system (Vest) at rest and during moderate physical activity (10-minute walk test) before and after sublingual nifedipine administration (10 mg). In all patients, both the systolic blood pressure and diastolic blood pressure were significantly reduced (P <.05) 6 minutes after nifedipine administration. In group 1, end-diastolic volume and ejection fraction decreased after 3 minutes and remained significantly lower (P <.05) than resting values until 10 minutes after drug administration, whereas end-systolic volume was unchanged. In group 2, nifedipine induced a minor decrease in end-diastolic volume and a slight but not significant decrease in ejection fraction and end-systolic volume. During the walk test, nifedipine induced similar changes in all parameters of cardiac performance in both groups.


CONCLUSIONS
In patients with impaired LV function, acute nifedipine administration has a negative effect on cardiac performance, which occurs before blood pressure reduction. On the other hand, during moderate physical activity, nifedipine does not affect the improvement in LV function.
Ferro
A
A
Department of Biomorphological and Functional Sciences, Nuclear Medicine Center of the National Council of Research (CNR), University Federico II, Napoli, Italy.
Salvatore
M
M
Cuocolo
A
A
D000286:Administration, Sublingual; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002306:Cardiac Volume / Q000187:drug effects / Q000502:physiology; D015444:Exercise / Q000502:physiology*; D005080:Exercise Test / Q000187:drug effects; D005260:Female; D015637:Gated Blood-Pool Imaging; D006333:Heart Failure / Q000000981:diagnostic imaging* / Q000503:physiopathology*; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage* / Q000494:pharmacology*; D012146:Rest / Q000502:physiology*; D013318:Stroke Volume / Q000187:drug effects / Q000502:physiology; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging* / Q000503:physiopathology*; D016277:Ventricular Function, Left / Q000187:drug effects* / Q000502:physiology*
D014665:Vasodilator Agents; D009543:Nifedipine